In addition to conventional chemotherapy, several drugs that target the molecular drivers of CRC—such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor pathways—have been used extensively to improve the survival of patients with mCRC (Cremolini et al. 2015; Venook et al. 2017; Bennouna et al. 2019; Heinrich et al. 2023) Current mCRC treatment guidelines recommend screening for mutations in genes such as KRAS, NRAS, and BRAF before selecting the chemotherapy regimen. This evidence concerns the gene EGFR and colorectal carcinoma.